(Q33425798)

26 July 2017

title

Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome (English)

1 reference

26 July 2017

main subject

irritable bowel syndrome

1 reference

Tougas G

1

1 reference

26 July 2017

Snape WJ Jr

2

1 reference

26 July 2017

Otten MH

3

1 reference

26 July 2017

Earnest DL

4

1 reference

26 July 2017

Langaker KE

5

1 reference

26 July 2017

Pruitt RE

6

1 reference

26 July 2017

Pecher E

7

1 reference

26 July 2017

Nault B

8

1 reference

26 July 2017

Rojavin MA

9

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

Alimentary Pharmacology & Therapeutics

26 July 2017

published in

1 reference

26 July 2017

volume

16

1 reference

26 July 2017

issue

10

1 reference

26 July 2017

page(s)

1701-1708

1 reference

Common functional gastrointestinal disorders: nonulcer dyspepsia and irritable bowel syndrome

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01347.X

Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01347.X

Review article: tegaserod

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01347.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01347.X

Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01347.X

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01347.X

Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01347.X

Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01347.X

Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01347.X

Effects of cisapride on corrected QT interval, heart rate, and rhythm in infants undergoing polysomnography

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01347.X

Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01347.X

10.1046/J.1365-2036.2002.01347.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference